Non-interventional study with Ra-223 dichloride assessing overall survival and effectiveness predictors for mCRPC patients in a real life setting in Germany (URANIS)
This observational prospective single arm cohort study
is designed to assess overall survival, symptomatic
skeletal event free survival and quality of life of metastatic Castration Resistant
Prostate Cancer (mCRPC) patients receiving Radium-
223 under real life conditions. In addition, time to next
tumor treatment (TTNT), mobility, quality of life and selfcare,
independence in activities of daily living and safety
will be assessed.
-Male patients diagnosed with castration resistant adenocarcinoma of the prostate (CRPC) with symptomatic bone metastases without known visceral metastases -Decision to initiate treatment with Radium-223 was made as per investigator’s routine treatment practice
-Patients participating in an investigational program with interventions outside of routine clinical practice and also in all non-interventional studies focusing on Radium- 223-dichloride.
Many Locations, Germany
E-mail: [email protected]
Phone: (+) 1-888-8422937
URANIS –Data collection in urological centers during treatment with Ra-223 dichloride (Xofigo) within the framework of a non-interventional study assessing overall survival (OS) and effectiveness predictors of Ra-223 dichloride treated mCRPC patients in a real life setting in Germany.